Cigna Group Affirms 2024 Earnings Guidance

TL;DR

Cigna Group confirms 2024 EPS $28.25-$29.05 and revenue $190B-$192B.

AI Summary

On September 3, 2024, The Cigna Group filed an 8-K to affirm its earnings guidance for the full year 2024. The company expects to achieve adjusted earnings per share (EPS) between $28.25 and $29.05, and adjusted revenue between $190 billion and $192 billion. This filing serves as an update and confirmation of previously issued financial outlook.

Why It Matters

This affirmation provides investors with continued confidence in Cigna Group's financial performance and outlook for the remainder of 2024.

Risk Assessment

Risk Level: low — The filing is a routine affirmation of previously provided guidance, indicating no new material negative information.

Key Numbers

• $28.25 - $29.05 — Adjusted EPS Guidance (Full year 2024 projected earnings per share.)
• $190B - $192B — Adjusted Revenue Guidance (Full year 2024 projected revenue.)

Key Players & Entities

• The Cigna Group (company) — Registrant
• September 3, 2024 (date) — Filing Date
• $28.25 (dollar_amount) — Lower end of projected adjusted EPS for 2024
• $29.05 (dollar_amount) — Upper end of projected adjusted EPS for 2024
• $190 billion (dollar_amount) — Lower end of projected adjusted revenue for 2024
• $192 billion (dollar_amount) — Upper end of projected adjusted revenue for 2024

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, Par Value $0.01 CI New York Stock Exchange , Inc. I
• $28.40 — ations on a per share basis of at least $28.40 per share. The Cigna Group previously

Filing Documents

• cigna8k.htm (8-K) — 32KB
• 0000950159-24-000274.txt ( ) — 204KB
• ci-20240903.xsd (EX-101.SCH) — 3KB
• ci-20240903_lab.xml (EX-101.LAB) — 33KB
• ci-20240903_pre.xml (EX-101.PRE) — 22KB
• cigna8k_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD Disclosure. 2024 Outlook Affirmation The Cigna Group (the "Company" or "our") officials expect to participate in meetings with investors and analysts over the next several weeks. During these meetings, The Cigna Group officials expect to reaffirm projected full year 2024 consolidated adjusted income from operations on a per share basis of at least $28.40 per share. The Cigna Group previously discussed its full year 2024 outlook in its press release and investor presentation dated August 1, 2024, and during the related investor conference call. The press release, presentation and the conference call transcript are available in the Investor Relations section of The Cigna Group's website located at www.thecignagroup.com. Forward-looking statements in these documents and the related call speak only as of the date they were made. Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group's management because it presents the underlying results of operations of the Company's businesses and permits analysis of trends in underlying revenue, expenses and shareholders' net income (loss). Adjusted income (loss) from operations is defined as shareholders' net income (loss) (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net realized investment results, amortization of acquired intangible assets and special items. The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (los

Forward-looking statements are subject to

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incidents; risks related to our use of artificial intelligence and machine learning; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operat

View Full Filing

View this 8-K filing on SEC EDGAR